pCPAO
pan-Canadian Pharmaceutical Alliance (pCPA): September 2021 Trends and Insights September 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 7 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation Key Take-Aways: The number of files under consideration at pCPA decreased slightly to 34 from last month’s high, while the average days under consideration had a…
pan-Canadian Pharmaceutical Alliance (pCPA): August 2021 Trends and Insights August 2021 Highlights: 8 products completed CADTH review 4 products initiated pCPA negotiations 10 negotiations were completed with an LOI No negotiations were closed without an LOI No files were closed without negotiation Key Take-Aways: The output of the pCPA in August was a high number of completed negotiations and slightly less files initiated for negotiations than usual. Partly…
Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant. The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA…
pan-Canadian Pharmaceutical Alliance (pCPA): July 2021 Trends and Insights July 2021 Highlights: 5 products completed CADTH review 5 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation Key Take-Aways: CADTH released no non-oncology recommendations in July. The volume of files under consideration remains relatively stable in July at 30, with no decrease in…
pan-Canadian Pharmaceutical Alliance (pCPA): June 2021 Trends and Insights June 2021 Highlights: 8 products completed CADTH review 12 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation Key Take-Aways: The volume of files under consideration remains stable with a slight decrease in the days under consideration in June relative to the last 6…
pan-Canadian Pharmaceutical Alliance (pCPA): May 2021 Trends and Insights May 2021 Highlights: 6 products completed CADTH review 3 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation Key Take-Aways: May sees continued consistency in both the volume of files under consideration and the average days under consideration which is hovering around the 5-month…
pan-Canadian Pharmaceutical Alliance (pCPA): April 2021 Trends and Insights April 2021 Highlights: 5 products completed CADTH review 6 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 file was closed without negotiation Key Take-Aways: The volume of files under consideration has remained relatively high and stable for the last 5 months (27-30), although the ratio of oncology to…
Toronto, May 4th, 2021 – MORSE Consulting is pleased to release their 2021 edition of the Canadian Reimbursement and Forecasting Timelines (CRaFT) report - a comprehensive source of reimbursement timelines and insights to inform forecasting and planning needs. MORSE has analyzed Canadian market access data from 2018 through 2020 to produce key reimbursement metrics. The report will support forecasting or planning necessary for launch in Canadian by providing critical insights on the public…
pan-Canadian Pharmaceutical Alliance (pCPA): March 2021 Trends and Insights March 2021 Highlights: 5 products completed CADTH review 3 products initiated pCPA negotiations 2 negotiations were completed with an LOI 3 negotiations were closed without an LOI 0 files were closed without negotiation Key Take-Aways: The average duration that files are under consideration reaches an annual peak of ~160 days. In addition, the number of files under consideration matches…
pan-Canadian Pharmaceutical Alliance (pCPA): February 2021 Trends and Insights February 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 6 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 5 new recommendations in February (28 files under pCPA consideration as of Feb 28) – down from 29 in January.…
pan-Canadian Pharmaceutical Alliance (pCPA): January 2021 Trends and Insights January 2021 Highlights: 4 products completed CADTH review 9 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in January (29 files under pCPA consideration as of January 31) – down from…
MORSE Consulting is pleased to release our Fourth Annual pCPA Year in Review Infographic – 2020 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2020. This infographic compares year-over-year metrics including: pCPA activity summary; the effect of COVID-19 on under-consideration files; average time to complete a negotiation; and files adjudicated by the pCPA by type in 2020. This infographic is an excerpt…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2020 Trends and Insights December 2020 Highlights: 8 products completed CADTH review 2 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation Beginning this month and over the next few months, the pCPA is introducing a Targeted Negotiation Process (TNP) to address selected files that have been on hold…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2020 Trends and Insights November 2020 Highlights: 4 products completed CADTH review 8 products initiated pCPA negotiation 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in November (24 files under pCPA consideration as of November 30) – down…
Introduction The Canadian Association for Healthcare Reimbursement (CAHR) held its first virtual Market Access 201 conference on November 24, 2020. Members of the MORSE team attended this conference and have prepared a brief summary of the key highlights. Disclaimer: Please note, this summary is based on our team’s interpretation of the discussion. Session 1. Keynote: Evolution of HTA in United States and the Impact on International Markets …
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pCPAO | MORSE Consulting Inc.
